NZ515613A - Chromeno[4,3,2-de]isoquinolines as potent dopamine receptor ligands - Google Patents
Chromeno[4,3,2-de]isoquinolines as potent dopamine receptor ligandsInfo
- Publication number
- NZ515613A NZ515613A NZ515613A NZ51561300A NZ515613A NZ 515613 A NZ515613 A NZ 515613A NZ 515613 A NZ515613 A NZ 515613A NZ 51561300 A NZ51561300 A NZ 51561300A NZ 515613 A NZ515613 A NZ 515613A
- Authority
- NZ
- New Zealand
- Prior art keywords
- improving
- treating
- compounds
- dopamine receptor
- receptor ligands
- Prior art date
Links
- 102000015554 Dopamine receptor Human genes 0.000 title abstract 3
- 108050004812 Dopamine receptor Proteins 0.000 title abstract 3
- 239000003446 ligand Substances 0.000 title abstract 2
- IZPCULKRJJKIRN-UHFFFAOYSA-N 8-oxa-15-azatetracyclo[7.7.1.02,7.013,17]heptadeca-1(17),2,4,6,9,11,13,15-octaene Chemical class N1=CC(C2=CC=CC=C2O2)=C3C2=CC=CC3=C1 IZPCULKRJJKIRN-UHFFFAOYSA-N 0.000 title 1
- 230000003389 potentiating effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000012239 Developmental disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 230000009084 cardiovascular function Effects 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000002124 endocrine Effects 0.000 abstract 1
- 210000000750 endocrine system Anatomy 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000010412 perfusion Effects 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000035790 physiological processes and functions Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14016699P | 1999-06-21 | 1999-06-21 | |
| PCT/US2000/016857 WO2000078765A2 (en) | 1999-06-21 | 2000-06-20 | CHROMENO[4,3,2-de]ISOQUINOLINES AS POTENT DOPAMINE RECEPTOR LIGANDS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ515613A true NZ515613A (en) | 2004-03-26 |
Family
ID=22490027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ515613A NZ515613A (en) | 1999-06-21 | 2000-06-20 | Chromeno[4,3,2-de]isoquinolines as potent dopamine receptor ligands |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6413977B1 (xx) |
| EP (1) | EP1192161B1 (xx) |
| JP (1) | JP2003502428A (xx) |
| KR (1) | KR20020010716A (xx) |
| AT (1) | ATE240959T1 (xx) |
| AU (2) | AU4536599A (xx) |
| BR (1) | BR0011711A (xx) |
| CA (1) | CA2373497A1 (xx) |
| DE (1) | DE60002867T2 (xx) |
| DK (1) | DK1192161T3 (xx) |
| ES (1) | ES2199837T3 (xx) |
| MX (1) | MXPA01013229A (xx) |
| NO (1) | NO20016255L (xx) |
| NZ (1) | NZ515613A (xx) |
| PT (1) | PT1192161E (xx) |
| WO (1) | WO2000078765A2 (xx) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004082567A2 (en) * | 2003-03-17 | 2004-09-30 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with dopamine receptor d1a (drd1) |
| AU2004308413A1 (en) * | 2003-12-23 | 2005-07-14 | Darpharma, Inc. | Co-administration of dopamine-receptor binding compounds |
| CA2643300C (en) * | 2006-02-21 | 2011-11-08 | Purdue Research Foundation | Trans-fused chromenoisoquinolines, synthesis and methods for use |
| WO2010124005A1 (en) | 2009-04-21 | 2010-10-28 | Purdue Research Foundation | Octahydrobenzoisoquinoline modulators of dopamine receptors and uses therefor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK297275A (da) * | 1974-08-07 | 1976-02-08 | Aspro Nicholas Ltd | Isoquinolinderivater |
| DK272182A (da) * | 1981-06-18 | 1982-12-19 | Univ Northeastern | Fremgangsmaade til fremstilling af oralt effektive aporphin-forbindelser eller dopamin-agonist-forbindelser med ikke aporphinstruktur eller farmaceutisk acceptable syreadditionssalte deraf |
| US5635506A (en) * | 1990-06-26 | 1997-06-03 | Research Corporation Technologies, Inc. | 1, 2-dihydro-3H-dibenzisoquinoline-1,3-dione anticancer agents |
| US6635642B1 (en) * | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
-
1999
- 1999-06-21 AU AU45365/99A patent/AU4536599A/en not_active Abandoned
-
2000
- 2000-06-20 EP EP00942943A patent/EP1192161B1/en not_active Expired - Lifetime
- 2000-06-20 WO PCT/US2000/016857 patent/WO2000078765A2/en active IP Right Grant
- 2000-06-20 KR KR1020017016235A patent/KR20020010716A/ko active IP Right Grant
- 2000-06-20 BR BR0011711-0A patent/BR0011711A/pt not_active IP Right Cessation
- 2000-06-20 ES ES00942943T patent/ES2199837T3/es not_active Expired - Lifetime
- 2000-06-20 DE DE60002867T patent/DE60002867T2/de not_active Expired - Fee Related
- 2000-06-20 DK DK00942943T patent/DK1192161T3/da active
- 2000-06-20 CA CA002373497A patent/CA2373497A1/en not_active Abandoned
- 2000-06-20 JP JP2001504931A patent/JP2003502428A/ja not_active Withdrawn
- 2000-06-20 MX MXPA01013229A patent/MXPA01013229A/es active IP Right Grant
- 2000-06-20 NZ NZ515613A patent/NZ515613A/xx unknown
- 2000-06-20 AU AU57492/00A patent/AU777522C/en not_active Ceased
- 2000-06-20 AT AT00942943T patent/ATE240959T1/de not_active IP Right Cessation
- 2000-06-20 PT PT00942943T patent/PT1192161E/pt unknown
- 2000-06-21 US US09/598,127 patent/US6413977B1/en not_active Expired - Lifetime
-
2001
- 2001-12-20 NO NO20016255A patent/NO20016255L/no not_active Application Discontinuation
-
2002
- 2002-07-02 US US10/188,579 patent/US6916832B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2373497A1 (en) | 2000-12-28 |
| EP1192161B1 (en) | 2003-05-21 |
| US6916832B2 (en) | 2005-07-12 |
| WO2000078765A2 (en) | 2000-12-28 |
| AU777522B2 (en) | 2004-10-21 |
| DE60002867T2 (de) | 2004-02-26 |
| AU777522C (en) | 2005-07-28 |
| MXPA01013229A (es) | 2002-11-04 |
| WO2000078765A3 (en) | 2001-06-28 |
| US20050080266A1 (en) | 2005-04-14 |
| EP1192161A2 (en) | 2002-04-03 |
| NO20016255D0 (no) | 2001-12-20 |
| US6413977B1 (en) | 2002-07-02 |
| JP2003502428A (ja) | 2003-01-21 |
| DK1192161T3 (da) | 2003-08-25 |
| AU5749200A (en) | 2001-01-09 |
| ES2199837T3 (es) | 2004-03-01 |
| ATE240959T1 (de) | 2003-06-15 |
| NO20016255L (no) | 2001-12-20 |
| DE60002867D1 (de) | 2003-06-26 |
| BR0011711A (pt) | 2002-03-26 |
| PT1192161E (pt) | 2003-09-30 |
| KR20020010716A (ko) | 2002-02-04 |
| AU4536599A (en) | 2001-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2366268A1 (en) | Pharmaceutical compositions for cns and other disorders | |
| MXPA02001306A (es) | Composiciones farmaceuticas para el tratamiento de enfermedades del sistema nervioso central y otras enfermedades. | |
| GR3022459T3 (en) | Quinuclidine derivative as substance p antagonist. | |
| MY107157A (en) | Quinuclidine derivatives. | |
| AP2002002465A0 (en) | Use of GABAA inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or Vitamin E for the treatment of cognitive disorders. | |
| CA2432085A1 (en) | Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands | |
| AU4818000A (en) | Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands | |
| ATE261448T1 (de) | Heteroaryl diazabicycloalkene, deren herstellung und verwendung | |
| PH31335A (en) | Naphthalamides as central nervous system agent. | |
| TNSN99177A1 (fr) | COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE PYRIDO [1, 2-a] PYRAZINE ET PROCEDE POUR LEUR PREPARATION | |
| PL330207A1 (en) | Aryl-substituted cyclic amines as selective ligands of d 3 dopamine | |
| TR199801164T2 (xx) | S�bstit�e edilmi� tetrasiklik tetrahidrofuran t�revleri. | |
| IL144181A0 (en) | USE OF PYRIDAZINO [4,5-b] INDOLE-1-ACETAMIDE DERIVATIVES FOR PREPARING MEDICINES FOR TREATING DISEASE RELATED TO THE DYSFUNCTION OF PERIPHERAL BENZODIAZEPIN RECEPTORS | |
| CA2263961A1 (en) | Cocaine receptor binding ligands | |
| HUP0202534A2 (hu) | Kondenzált pirrolkarboxamidok és a vegyületeket tartalmazó gyógyászati készítmények | |
| NZ515613A (en) | Chromeno[4,3,2-de]isoquinolines as potent dopamine receptor ligands | |
| DE69431050D1 (de) | PYRIDO[2,3-b](1,4)BENZODIAZEPINONE ALS M2-REZEPTORLIGAND ZUR BEHANDLUNG NEUROLOGISCHER STÖRUNGEN | |
| TNSN00178A1 (en) | Fused pyrrolecaboxamides; a new class of gaba brain receptor ligands | |
| CA2249562A1 (en) | Certain fused pyrrolecarboxamides as gaba brain receptor ligands | |
| CA2180155A1 (en) | Naphthylamides as central nervous system agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed |